NetworkNewsBreaks

MondayAug 10, 2026 12:03 pm

NetworkNewsBreaks – EquiDeFi Prometheus AI SPV Opens Pre-IPO AI Investment Opportunity to Accredited Investors 

EquiDeFi Prometheus AI SPV, LLC has partnered with EquiDeFi, Ltd. to launch a private offering providing accredited investors with indirect exposure to Series B preferred shares of a major pre-IPO artificial intelligence company co-founded by Jeff Bezos and Vikram Bajaj. The AI company, which is developing machine learning, agent-based and generative AI tools aimed at accelerating product design, testing and manufacturing, recently raised $12 billion in Series B funding at a $29 billion pre-money valuation. Subscriptions for the SPV are scheduled to open Aug. 12, 2026, at 9 a.m. ET, with a minimum investment of $10,000. Investors will receive membership interests in the SPV representing their pro rata participation in an investment structure…

Continue Reading

MondayAug 10, 2026 11:45 am

NetworkNewsBreaks – American Fusion Inc. (OTC: AMFN) Appoints John Gerdin as Independent Director and Strategic Advisor 

American Fusion (OTC: AMFN) announced the appointment of John Gerdin to its board of directors as an independent director and strategic advisor. Gerdin brings nearly three decades of experience in international finance, financial structuring and cross-border advisory work across Europe, Asia and North America. In his advisory role, he is expected to provide guidance on corporate finance, international capital markets, strategic partnerships and long-term corporate development as American Fusion advances its proprietary Texatron(TM) Fusion Engine(TM) program. American Fusion said Gerdin appointment adds financial and capital markets experience as the company strengthens its corporate infrastructure and pursues its stated objective of progressing to the OTCQB Market, with a longer-term objective of qualifying for a…

Continue Reading

MondayAug 10, 2026 11:33 am

NetworkNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Surpasses $5 Million in 2026 AI-Related Orders 

Safe Pro Group (NASDAQ: SPAI) announced that total AI-related orders in 2026 have surpassed $5 million in aggregate contract value, driven by government awards for its AI-powered threat detection and mapping solutions, including new government subcontracts received in August. Through early August, Safe Pro has received eight contracts for its AI edge compute and rapid imagery processing technologies for applications using aerial drones and ground-based autonomous systems. The company noted that order values represent contract awards and may not yet be fully recognized as revenue. Safe Pro said its AI software has been selected by the U.S. Army, U.S. Air Force and multiple defense prime contractors for…

Continue Reading

MondayAug 10, 2026 10:50 am

NetworkNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on AI Power, Infrastructure Demand

AZIO AI Holdings (NASDAQ: AZIO) is featured in an AINewsWire editorial titled “As AI Races Ahead, the Real Battle Is Over Power and Infrastructure,” examining how accelerating artificial intelligence adoption is driving demand for the physical infrastructure required to support AI computing. The editorial highlights AZIO AI integrated infrastructure strategy, including its planned 500-megawatt Texas AI data-center campus, Master Services Agreement with AT&T for enterprise fiber connectivity and power purchase and AI infrastructure hosting agreement with Power Champion Investment Limited. The editorial also highlights AZIO AI recently announced letter of intent with Power Champion for the proposed acquisition of 128…

Continue Reading

MondayAug 10, 2026 9:30 am

NetworkNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Secures $10 Million Strategic Private Placement With Eric Sprott

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) announced a strategic non-brokered private placement with Eric Sprott for gross proceeds of $10 million. The financing consists of 4 million units priced at $2.50 each, to be subscribed for by 2176423 Ontario Ltd., a corporation beneficially owned by Sprott. Each unit includes one common share and one warrant exercisable at $3.25 for 24 months. Closing is anticipated on or about Aug. 17, 2026, subject to customary conditions, including Canadian Securities Exchange approval. MAX Power…

Continue Reading

MondayAug 10, 2026 9:10 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible. Lucid-MS…

Continue Reading

MondayAug 10, 2026 9:00 am

NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million

Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, up from $2 million in the year-ago period, driven by approximately $11 million in net sales of TONMYA. The fibromyalgia treatment recorded 12,592 total prescriptions during the quarter, up 100% sequentially, while new patient prescriptions increased 36% and refills rose 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare and Medicaid channels, with coverage expected to reach approximately 145 million lives when a managed Medicare agreement takes effect Jan. 1, 2027. Tonix also continued advancing its clinical pipeline, enrolling the first…

Continue Reading

FridayAug 07, 2026 2:52 pm

NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for a potential FDA Premarket Approval submission, expanding commercialization efforts in Europe following CE Mark approval, and optimizing manufacturing for scalability and consistency. To view the full article, visit https://nnw.fm/q63mp About Regentis Biomaterials Ltd. Regentis Biomaterials is a…

Continue Reading

FridayAug 07, 2026 2:10 pm

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal of protecting and potentially restoring the myelin sheath rather than primarily modulating the immune system. The company submitted an IND application to the FDA for a Phase 2 trial and is supporting development through an imaging collaboration…

Continue Reading

FridayAug 07, 2026 12:56 pm

NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://nnw.fm/U12or About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

Continue Reading